...
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes
【24h】

Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes

机译:糖尿病药物对2型糖尿病患者心血管风险和替代指标的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To evaluate the effect of diabetes medications on the risk of cardiovascular disease and surrogate markers.Data Sources: Literature was accessed through MEDLINE (1950-July 2008) and PubMed using multiple terms for diabetes, cardiovascular risk, surrogate markers, and diabetes medications. In addition, reference citations from publications were reviewed.Study Selection and Data Extraction: English-language articles that met the above criteria, with clinical relevance, were evaluated.Data Synthesis: Evidence regarding the effect of diabetes medications on cardiovascular risk is sparse, with information on their effects on surrogate markers more widely available. Recent evidence demonstrates that glycemic control alone may not reduce the risk of macrovascular events. Multiple trials were reviewed to determine the effect of diabetes medications on this risk, as well as the effect on surrogate markers (eg, blood pressure, cholesterol, body weight). Metformin and acarbose demonstrated significant reductions in macrovascular events, including myocardial infarction. Data regarding sulfonylureas, thiazolidinediones, and insulin are conflicting. Pioglitazone may reduce cardiovascular events, except heart failure, whereas rosiglitazone may increase these events. Until direct evidence can be obtained, the full effect of diabetes medications on cardiovascular risk is unknown.Conclusions: Current literature provides little support that diabetes medications may lower the risk of cardiovascular events while some agents may increase this risk. Of the drugs available, metformin may be the least detrimental. Current literature regarding other diabetes medications provides conflicting results on their effect on cardiovascular outcomes. In the meantime, practitioners should treat all targets of cardiovascular risk in patients with diabetes.
机译:目的:评估糖尿病药物对心血管疾病风险和替代指标的影响。数据来源:文献通过MEDLINE(1950年7月至2008年7月)和PubMed获得,涉及糖尿病,心血管疾病风险,替代指标和糖尿病药物等多个术语。此外,还对出版物的参考文献进行了审查。研究选择和数据提取:对符合上述标准且与临床相关的英语文章进行了评估。数据综合:关于糖尿病药物对心血管风险影响的证据稀疏,有有关它们对替代标记的影响的信息更为广泛。最近的证据表明,仅控制血糖并不能降低大血管事件的风险。回顾了多项试验,以确定糖尿病药物对这种风险的影响以及对替代指标(例如血压,胆固醇,体重)的影响。二甲双胍和阿卡波糖证明了包括心肌梗塞在内的大血管事件的显着减少。有关磺酰脲类,噻唑烷二酮类和胰岛素的数据相互矛盾。吡格列酮可能减少心力衰竭以外的心血管事件,而罗格列酮则可能增加这些事件。在获得直接证据之前,尚不清楚糖尿病药物对心血管风险的全部效果。结论:目前的文献很少支持糖尿病药物可降低心血管事件的风险,而某些药物可能会增加这种风险。在可用药物中,二甲双胍的危害最小。有关其他糖尿病药物的最新文献对它们对心血管结局的影响提供了相互矛盾的结果。同时,从业人员应治疗糖尿病患者的所有心血管疾病靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号